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Abstract
Background: A recent model for activation of the zymogen form of matrix metalloproteinase 2
(MMP-2, also known as gelatinase A) has suggested that interactions between the SIBLING protein
bone sialoprotein (BSP) and MMP-2 leads to conformational change in MMP-2 that initiates the
conversion of the pro-enzyme into a catalytically active form. This model is particularly relevant to
cancer cell metastasis to bone since BSP, bound to the αvβ3 integrin through its arginine-glycine-
aspartic acid motif, could recruit MMP-2 to the cell surface.
Methods: We critically assessed the relationship between BSP and proMMP-2 and its activation
using various forms of recombinant and purified BSP and MMP-2. Gelatinase and collagenase assays,
fluorescence binding assays, real-time PCR, cell culture and pull-down assays were employed to
test the model.
Results: Studies with a fluorogenic substrate for MMP-2 showed no activation of proMMP-2 by
BSP. Binding and pull-down assays demonstrated no interaction between MMP-2 and BSP. While
BSP-mediated invasiveness has been shown to depend on its integrin-binding RGD sequence,
analysis of proMMP-2 activation and the level of membrane type 1 (MT1)-MMP in cells grown on a
BSP substratum showed that the BSP-αvβ3 integrin interaction does not induce the expression of
MT1-MMP.
Conclusion: These studies do not support a role for BSP in promoting metastasis through
interactions with pro-MMP-2.
Background
Bone sialoprotein (BSP) is a highly glycosylated and sul-
fated phosphoprotein that is expressed largely in mineral-
izing tissues [1] but is also associated with cancer
metastasis. Elevated levels of BSP have been reported in
tumors and serum from patients with breast, lung, pros-
tate, or thyroid cancer [2]. Expression of BSP in cancer has
been associated with metastasis of tumor cells to bone [3]
as well as hydroxyapatite crystal formation in tumor tis-
sues and breast cancer cell lines [4].
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Matrix metalloproteinases (MMPs) are a family of zinc-
dependent endopeptidases that cooperate to modulate
homeostasis of the extracellular environment by regulat-
ing oncogenic signaling networks and degrading extracel-
lular matrix components, thereby contributing to tumor
cell progression [5-7]. MMP-2 (also known as gelatinase
A) is made up of five structural domains including an
inhibitory pro-domain [8-10]. Functional activity is regu-
lated by enzymatic removal of the inhibitory pro-domain.
A primary mechanism of proMMP-2 activation involves
formation of a tri-molecular complex on cell surfaces
involving tissue inhibitor of metalloproteinase-2 and
membrane type 1-MMP (MT1-MMP) [11,12]. An alterna-
tive mechanism for controlling MMP-2 activity has
invoked apparent structural changes that arise from spe-
cific interactions between BSP and proMMP-2 [13,14]. It
was reported that upon binding to BSP the proteolytic
activity of proMMP-2 increased significantly, but paradox-
ically without removal of the inhibitory pro-peptide [13].
It was suggested that BSP-mediated conformational
changes upon partnering with proMMP-2 may facilitate
removal of the inhibitory pro-peptide by another pro-
tease, which is similar to the binding and activation of
proMMP-2 by MT1-MMP. A 26 amino acid domain of BSP
appears to be involved in the displacement of MMP-2's
propeptide from the active site of MMP2, thereby enhanc-
ing protease activity [14].
Since BSP and MMP-2 are associated with tumor progres-
sion [2,15-17,7], the potential modulation of proMMP-2
activity by BSP is particularly relevant to tumor metastasis.
We critically assessed potential interactions between BSP
and proMMP-2 that mediate proMMP-2 activation.
Methods
Reagents
Recombinant proMMP-2 was produced as described [18].
Bacterial recombinant rat BSP, rat native BSP, and BSP
fragments were produced by Harvey Goldberg (University
of Western Ontario). The BSP fragments contained amino
acids 1–100, 99–200, 200–301, 51–150, and 99–250) of
BSP. Recombinant human BSP expressed in human bone
marrow stromal cells was from N.S. Fedarko (Johns Hop-
kins). Porcine BSP, G2 BSP, human BSP, and pig OPN
were purified from 0.5 M EDTA and 4 M guanidine-HCL
(G2) extracts of bone tissues. OPN was purified from
bovine milk.
Cell Culture
Human breast cancer cell lines MDA-MB231, MCF7,
T47D, and fibrosarcoma HT1080 cells were obtained
from ATCC. Rat bone marrow stromal cells were from S.
Pitaru (Tel Aviv, Israel). Human gingival fibroblasts were
grown in primary culture and for production of activated
MMP2, cells were treated with concanavalin A. Cells were
maintained in α-minimum essential medium (MEM)
containing 10% fetal bovine serum. T47D cells were
maintained in a monolayer culture in RPM1 containing
1% Glutamax 1 and10% FBS.
Cell Culture on BSP substratum
Cells were seeded on to 24-well plates coated with 30 nM
rat recombinant or rat native BSP. For analysis of
proMMP-2 activation, conditioned medium was collected
after 24 hours in serum-free medium, concentrated, and
analyzed for gelatinase activity by zymography. To ana-
lyze MT1-MMP mRNA, cells were seeded at 1.0 × 106 cells/
mL on a non-tissue culture 96-well ELISA plates coated
with rat native BSP (0.15 μM) or poly-L-Lysine (0.1%).
Tryptophan fluorescence binding assay
Since BSP contains no tryptophans, the binding of BSP to
proMMP-2 was measured from the shift in tryptophan flu-
orescence of proMMP-2 (15 tryptophan residues) (excita-
tion = 295 nm; emission = 300–400 nm) after addition of
BSP, BSP peptides, or control proteins (from 17 nM-1165
nM) to proMMP-2 (333 nM). All spectra were corrected
for buffer and dilution effects. Under these conditions,
fluorescence observed was attributed exclusively to tryp-
tophans from proMMP-2 as described previously [13]. To
estimate dissociation constants (Kd), a saturation curve for
BSP-proMMP-2 complex formation was obtained. Kd val-
ues were calculated using the Scatchard equation r/[free
BSP] = n/Kd - r/Kd where n represents the number of bind-
ing sites and r  =  [bound BSP]/[total proMMP-2]. Each
experiment was carried out in triplicate.
Analysis of proMMP-2 auto-activation
Gelatinase activities were determined by gelatin zymogra-
phy [19]. BSP-mediated proMMP-2 activation was moni-
tored by incubating 0.2 ng/2 μL of BSP with proMMP-2
(0.05, 0.2, 0.5, or 2 ng) and adding collagenase assay
buffer[20] (total volume of 8 μL). For positive controls,
activated MMP-2 was obtained from concanavalin A-
treated fibroblast-conditioned medium. After 4 hours of
incubation at 21°C, samples extracted in SDS-PAGE sam-
ple buffer (without DTT) were analyzed by gelatin zymog-
raphy.
Gelatinase substrate assay
ProMMP-2 activity was measured with a highly quenched,
fluorescein-labeled (DQ) gelatin substrate at 21°C. Upon
proteolytic digestion, its fluorescence is revealaed and can
be used to measure enzymatic activity. Each assay was
conducted at 21°C in collagenase assay buffer. ProMMP-
2 (1.4 nM or 2.8 nM) was added to 12.5 μg/mL substrate
in the presence or absence of BSP (4.9 nM or 9.8 nM).
Cleavage of the substrate was monitored using a micro-
plate based multi-detection reader (485 nm excitation,
520 nm emission filters; FLUOstar OPTIMA, BMGBMC Cancer 2009, 9:121 http://www.biomedcentral.com/1471-2407/9/121
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Labtech, Offenburg, Germany). Changes in fluorescence
intensity were monitored in relation to controls: substrate
+ BSP, substrate or proMMP-2 as negative controls, and
substrate + proMMP-2 activated with aminophenylmercu-
ric acetate (APMA) as a positive control.
Binding assays
For analysis of bound and unbound proMMP-2, 25 ng/50
μL of the pro-enzyme was added to ELISA plates coated
with various concentrations of pBSPE (porcine BSP-
extract), pBSPG2 (G2-extract), human bone proteins
(hBP), pig bone OPN (OPN), and incubated for 1 hour at
21°C. Supernatants and bound proteins were analyzed by
gelatin zymography. For analysis of potential adaptor
molecules, conditioned medium from cells was added to
ELISA plates coated with 40 nM rat recombinant BSP,
BSA, or gelatin and incubated for 1 hour at 21°C. Super-
natant and bound proteins extracted with sample buffer
were analyzed for gelatinase activity by zymography. For
analysis of potential adaptor molecules, 200 μL of condi-
tioned medium collected from MDA-MB231, rat bone
marrow stromal cells, HT1080 cells, and human gingival
fibroblasts at 60 hours after seeding was added to a 96-
well ELISA plated coated with 40 nM rat recombinant
BSP, BSA or gelatin. Each mixture was incubated for 1
hour at 21°C. Supernatant and bound proteins extracted
with sample buffer were analyzed for gelatinase activity
using zymography.
Biotinylation of bone proteins
For biotinylation, 22 moles of biotin were used per mole
of bone proteins. Correspondingly, appropriate amount s
of biotin (1 mg of biotin dissolved in mL DMSO) were
added to each protein preparation. The mixtures were
stirred for 2 hr at 4°C. To remove free biotin, the mixtures
were desalted on a 10 mL desalting column equilibrated
in 50 mM ammonium bicarbonate buffer, pH 8.5. Bioti-
nylation of the eluate fractions was assessed using dot blot
analysis, where 2 μL of each fraction was taken and
probed with streptavidin horseradish peroxidase. Finally,
the highly biotinylated fractions were pooled, speed vacu-
umed and reconstituted in water.
Solution phase binding assay
Biotinylated BSP was utilized to examine the potential
interaction between BSP and proMMP-2 in solution and
in these experiments 25 ng proMMP-2 was incubated with
5 μg biotinylated protein in 50 μL Tris-Tween (0.05%; pH
~7.6) for 1 hour at 21°C. To isolate BSP along with bound
proteins, streptavidin beads were added, incubated for 30
minute at 21°C, centrifuged, and supernatants were col-
lected. Beads were rinsed and supernatants and bead elu-
ates were analyzed by gelatin zymography. Controls
included no MMP-2 and no BSP.
Real-time PCR
RNA was extracted from cells using a Stratagene RNA min-
iprep kit. Total RNA (1 μg) was reverse transcribed and
real-time PCR for MT1 was performed using the TaqMan®
Gene Expression Assay system using validated probes
human MT1-MMP (no. 4331182) and eukaryotic 18S
endogenous control (no. 4319413E).
Statistical analysis
All assays were repeated at least 3 times in 3 separate
experiments. For data involving continuous variable, the
means and standard errors of the mean were calculated
and where appropriate, analysis of variance was used to
examine differences between multiple groups.
Results
BSP induces non-specific quenching of proMMP-2
Due to variations of BSP phosphorylation of serines and
O- and N-linked glycosylation, recombinant or native rat
BSP (purified from long bones of adult rats) were used in
binding studies to assess binding between proMMP-2 and
BSP. Intrinsic tryptophan fluorescence measurements
demonstrated that titration of proMMP-2 with BSP
resulted in a proportional quenching of MMP tryptophan
emission spectra (Fig. 1), suggestive of direct protein-pro-
tein interactions. Since proMMP-2 contains 15 tryp-
tophan residues, whereas BSP contains none, the
quenching of the tryptophan fluorescence signal suggests
that proMMP-2 undergoes significant conformational
changes, exposing internal tryptophan residues to a more
polar environment in the presence of BSP with an appar-
ent Kd of 0.27 ± 0.11 μM. However, control studies using
osteopontin and RNase A in the same system also yielded
a similar quenching of the proMMP-2 tryptophan emis-
sion spectra as well as the derivation of similar Kd values.
The human recombinant BSP that was used previously to
detect binding between BSP and proMMP-2 [13] may
have included modifications necessary for measurement
of potential interactions. Accordingly, the effect of post-
translational modifications on the proposed interaction
between BSP and MMP-2 was investigated using human
recombinant BSP obtained from N. Fedarko (Fig. 2). The
emission peak in intrinsic fluorescence was observed at
~335 nm, which is in contrast to the previous study [13]
that reported an emission peak at 360 nm and an interac-
tion between proMMP-2 and BSP with a kd  in the
nanomolar range. When the MMP-binding site within
BSP was studied by intrinsic fluorescence using BSP pep-
tides (Fig. 3), each BSP fragment showed quenching of the
MMP-2 tryptophan fluorescence signal, similar to the
emission spectra obtained using the full-length BSP mol-
ecule and the control proteins suggesting non-specific
interactions.BMC Cancer 2009, 9:121 http://www.biomedcentral.com/1471-2407/9/121
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BSP does not modify proMMP-2 activity
To examine potential activation induced by the addition
of BSP to proMMP-2, zymography was employed to esti-
mate the amount of mature enzyme of smaller molecular
weight (59 or 62 kDa). In concentrations where BSP is in
excess of proMMP-2, there was no evidence for significant
removal of the pro-domain (Fig. 4) although in positive
controls, proMMP-2 that had been activated in concanav-
alin A-treated cells showed lower molecular mass MMP-2
(Fig. 4, lanes 9, 10), consistent with cleavage of the pro-
peptide and enzyme activation. When zymography bands
were further assessed, each BSP-treated proMMP-2 sample
resulted in an identical migration pattern as that of
untreated enzyme. This is consistent with previous find-
ings indicating that BSP binding does not induce signifi-
cant cleavage of the pro-peptide [13]. Therefore, BSP-
treated proMMP-2 migrates as an intact molecule (Mr of
~66 kDa) on zymograms since the pro-peptide remains
attached.
The effect of BSP on proMMP-2 activity was examined
using fluorescent labeled gelatin substrate. Treatment of
proMMP-2 with increasing concentrations of recom-
binant BSP or fetal porcine BSP did not alter enzymatic
activity compared to latent enzyme alone (Fig. 5). Using
the same substrate, the ability of OPN to activate
proMMP-3 was assayed, but activity above control values
was also not observed. Since BSP may interact with
proMMP-2 so that the inhibitory pro-peptide is removed
from the active site [13], hence exposing the active site, we
considered that the presence of BSP would lead to signifi-
cant cleavage (auto-activation) to the lower molecular
weight, active MMP-2. However, we found no increase in
the amount of pro-peptide-free MMP-2 by zymography
confirming the fluorescent gelatin cleavage assays. Fur-
ther, BSP did not mediate proMMP-2 catalytic activity as
shown with the fluorescent substrates.
Fluorescence emission spectrum of BSP-treated proMMP-2 Figure 1
Fluorescence emission spectrum of BSP-treated proMMP-2. proMMP-2 (333 nM) was incubated with increasing con-
centrations of native or recombinant BSP, OPN or RNase A (negative controls). Emission scans were obtained after each addi-
tion of BSP (excitation wavelength of 295 nm). In all cases, titrations of proMMP-2 yielded proportional quenching of the 
proMMP-2 tryptophan emission spectra.
Tryptophan fluorescence profile Figure 2
Tryptophan fluorescence profile. proMMP-2 (333 nM) 
was incubated with nM amounts of native BSP. Emission 
scans were obtained after each addition of BSP (excitation 
wavelength = 295 nm). Emission peak was at 335 nm.BMC Cancer 2009, 9:121 http://www.biomedcentral.com/1471-2407/9/121
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Analysis of bound and unbound MMP-2
Despite the lack of significant pro-peptide cleavage when
proMMP-2 dose response curves to BSP were examined,
we hypothesized that BSP-induced activation might
involve only a fraction of the total amount of enzyme. We
used ELISA plates to resolve BSP-bound and unbound
fractions, which allows for higher resolution examina-
tions of the BSP-proMMP-2 interactions. Previous find-
ings have suggested a 1:1 stoichiometry of binding
between BSP and proMMP-2 and a Kd value of 2.9 ± 0.9
nM [13]. Such a strong affinity should allow for detection
of the interaction. However, our data showed no binding
between the proMMP-2 and BSP as detected when the
BSP-bound (extract) and unbound (supernatant) frac-
tions were analyzed by zymography (Fig. 6).
We considered that the lack of association between
proMMP-2 and BSP could be a consequence of disruption
of a binding motif from fixing BSP to a hydrophobic sur-
face. Accordingly, we assessed the ability of BSP to associ-
ate with proMMP-2 in solution. Bone proteins were
biotinylated, incubated with proMMP-2 and isolated
using streptavidin beads. When bead-bound entities were
assessed by zymography, each bead-purified bone protein
showed no evidence of MMP-2 binding (data not shown).
Further, MMP-2 was recovered entirely in the latent form
(Mr of 66 kDa) in the supernatant. Alternatively, when
biotinylated bone proteins were pre-bound to streptavi-
din beads, followed by the addition of proMMP-2, similar
results were observed.
Interactions between BSP peptides and proMMP-2 Figure 3
Interactions between BSP peptides and proMMP-2. proMMP-2 (333 nM) was incubated with nM amounts of BSP pep-
tides. Emission scans were obtained after each addition of BSP (excitation wavelength = 295 nm). Emission spectra show that 
titration of proMMP-2 with each BSP peptide yielded proportional quenching of the proMMP-2 emission spectra.
Zymography analysis of BSP-treated proMMP-2 Figure 4
Zymography analysis of BSP-treated proMMP-2. ProMMP-2 was incubated with (lanes 5–8) or without (lanes 1–4) 
increasing amounts of BSP for 4 hours at 21°C, and resolved by zymography. ConA cell-activated MMP-2 were used as stand-
ards (lanes 9–10). Lane 1, 2 ng proMMP-2; lane 2, 0.5 ng proMMP-2; lane 3, 0.2 ng proMMP-2; lane 4, 0.05 ng proMMP-2; lane 
5, 2 ng proMMP-2 + 2 ng BSP; lane 6, 0.5 ng proMMP-2 + 2 ng BSP; lane 7, 0.2 ng proMMP-2 + 2 ng BSP; lane 8, 0.05 ng 
proMMP-2 + 2 ng BSP; lanes 9 and 10, 0.05 ng conA activated MMP-2.
1        2       3        4        5        6      7       8        9      10       
proMMP-2
MMP-2BMC Cancer 2009, 9:121 http://www.biomedcentral.com/1471-2407/9/121
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Analysis of potential adaptor molecules
Because of the lack of any evidence of specific binding of
proMMP-2 to BSP, the need for potential adaptor mole-
cules in this interaction was examined using solid phase
binding assay on ELISA plates followed by zymography.
Serum-free conditioned medium collected from MDA-
MB231, rat bone marrow cells, HT1080 or human gingi-
val fibroblasts were used as a source of MMP-2 and added
to BSP that was conjugated to an ELISA plate. Since the
reported binding between BSP and proMMP-2 was ini-
tially identified by a co-purification of proMMP-2 and
recombinant BSP expressed in bone marrow cells [13], we
hypothesized that given the absence of a direct interaction
then complexes with other proteins might be required,
similar to the TIMP-2 bridge between the physiological
activator MT1-MMP and MMP-2 [18]. Nonetheless,
zymography analysis of BSP-bound (extract) and
unbound (supernatant) fractions revealed that latent and
active MMP-2 secreted by bone marrow cells (Fig. 7), as
well as the other cell lines, were recovered entirely in the
supernatant, unbound fraction as observed for recom-
binant proMMP-2.
ProMMP-2 activation is unaffected by cellular adhesion to 
BSP
Despite the lack of direct or indirect interaction observed
between BSP and proMMP-2, clustering of the α2β1
integrins in cancer cells stimulated by fibrillar collagen
has been shown to promote tyrosine kinase-mediated
events that result in expression of MT1-MMP and
proMMP-2 activation [21]. To investigate the conse-
quences of integrin αvβ3 clustering by BSP, the levels of
proMMP-2 activation in MDA-MB231, MCF7, and T47D
cells grown on BSP substrata were compared to that of
cells grown on plastic. There was a similar level of
proMMP-2 activation in cells after attachment to BSP in
comparison to cells grown on plastic (Fig. 8). Since
proMMP-2 activation is directly associated with the level
of MT1-MMP activity, these results indicated that cellular
binding to BSP via integrin αvβ3 does not modify MT1-
MMP activity on the cell surface. Previously we have
shown that proMMP-2 does not directly bind αvβ3[22].
ProMMP-2 activity after incubation with BSP Figure 5
ProMMP-2 activity after incubation with BSP. ProMMP-2 (1.4 or 2.8 nM) was incubated with recombinant BSP (rBSP) or 
native BSP (nBSP) (4.9 or 9.8 nM) and 12.5 μg/mL fluorescent substrate. Results are values calibrated with fluorescence from 
substrate + BSP controls. Fluorescence levels of other controls, including substrate only, substrate + proMMP-2 and substrate 
+ APMA-activated enzyme, are also shown.
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Cellular adhesion to BSP does not alter MT1-MMP 
transcript level
Since the activity of MT1-MMP is regulated at multiple
steps, differences in MT1-MMP expression may not be
detected by analysis of proMMP-2 activation. Accordingly,
MT1-MMP mRNA levels were analyzed by real time RT-
PCR to investigate quantitatively whether MT1-MMP
mRNA levels are different between cancer cells grown on
a BSP substratum and on poly-L-Lysine. Real-time PCR
results (Fig. 9) did not detect any significant changes in
the MT1-MMP transcript level by stimulation with BSP (p
> 0.2), which was consistent with an unaltered level of
MT1-MMP activity as observed by zymography.
Discussion
Cellular invasion in metastasis is a coordinated event that
involves multiple metabolic processes and cellular com-
ponents, including deployment and activation of cell
adhesion molecules and proteolytic enzymes. Frequently,
multimers of proteases show increased catalytic efficiency
and in the plasma membrane, enabling focal proteolysis
under cellular control. MMPs have traditionally been
associated with tumor cell invasion and metastasis, in par-
ticular MMP-2 and its activator MT1-MMP. MMP-2 is
uniquely activated on the cell surface by MT-MMPs in a
highly regulated process after complex formation of pro-
and active MMP-2 with MT1-MMP and TIMP-2 [23,12].
Extracellularly, clustering by heparin or ConA [24] and
claudin [25], increases MMP-2 activation. Recently, spe-
cific interactions between BSP and latent forms of MMP-2
have been reported that resulted in activation of proMMP-
2 [13]. We assessed here the ability of various forms of
BSP to bind and activate proMMP-2. We investigated the
possibility that BSP activated proMMP-2 by analysis of
gelatinase activity using a fluorescent substrate, but the
analysis showed no activation of proMMP-2. Further,
when OPN, another SIBLING protein, was assessed in
proMMP-3 activation using the same substrate, no activa-
tion could be detected. Therefore, BSP does not appear to
be involved in the activation of proMMP-2.
After careful examination of the conditions used for acti-
vation in the previous study [13], we noticed that despite
a reported Kd value of 2.9 ± 0.9 nM, a 500-fold molar
excess of BSP was necessary to demonstrate proMMP acti-
vation. We repeated these experiments using the human
BSP at this same ratio but again found no activation.
Given the potential ability of BSP to promote displace-
ment of pro-peptides from active sites of proMMP-2 [13],
we considered that there may be auto-activation of the
latent enzyme in the presence of BSP. However, when
proMMP-2 was treated with BSP, the proMMP-2 migrated
as an intact molecule on zymograms, indicating that BSP
does not activate proMMP-2.
Activation of MMP-2 requires unidentified protein-pro-
tein interactions, one of which might involve BSP. Extra-
cellularly, one of the known interactors is native type I
collagen, which results in the lateral association of MT1-
MMP to accelerate activation of progelatinase A [26,27].
ProMMP-2 recovery in BSP-unbound sample Figure 6
ProMMP-2 recovery in BSP-unbound sample. ProMMP-2 (0.5 mM) was added to decreasing concentrations of indicated 
SIBLING proteins (40 mM, 20 mM, 10 mM, 5 mM, 2.5 mM, 1.2 mM, 0.6 mM, and 0 mM) coated on an ELISA plate, and incu-
bated at 21°C for 4 hours. Samples of the unbound (Supernatant) and bound (Extract) proteins were extracted in SDS sample 
buffer, and analyzed by zymography. proMMP-2 was recovered completely in the latent form in the unbound (Supernatant) 
fractions.BMC Cancer 2009, 9:121 http://www.biomedcentral.com/1471-2407/9/121
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As a result of our inability to detect BSP-induced activa-
tion of proMMP-2, we examined the interaction of these
two proteins using binding assays. Since previous findings
[13] have suggested a 1:1 stoichiometric binding between
BSP and proMMP-2 with a Kd value in the low nanomolar
range, such an affinity presumably allows detection of the
interaction using less sensitive assays such as affinity
adsorption. However, we found no evidence of interac-
tion between BSP and proMMP-2 using these assays.
To address the possibility of cell-derived adaptor mole-
cules required for the BSP-proMMP-2 interaction, BSP was
incubated with conditioned medium collected from
breast cancer cells, bone marrow cells or human gingival
fibroblasts. As observed for recombinant proMMP-2,
latent and active MMP-2 secreted by cancer cells also did
not bind to BSP. Notably, BSP is highly heterogeneous as
a result of variations in the phosphorylation of serines
and O- and N-linked glycosylation [28]. Presumably, BSP
expressed by diverse cells types is modified differently,
and variations in post-translational modifications may
determine the activity of these proteins and the binding
and activation of proMMP-2. Accordingly we employed
recombinant BSP, BSP purified from bone, or recom-
binant human BSP to assess binding to proMMP-2. As we
were unable to detect binding of any of the BSPs to
proMMP-2, there is evidently a need to re-assess the
potential ability of BSP to bind to and activate proMMP-2
in the context of cancer cell metastasis although we can-
not rule out the possibility that much more highly glyco-
sylated BSP than the bovine BSP we used here could
conceivably mediate an interaction with proMMP2.
MMP-2 from conditioned medium recovery in BSP-unbound fraction Figure 7
MMP-2 from conditioned medium recovery in BSP-unbound fraction. Serum-free conditioned media collected from: 
1) MDA-MB231, 2) rat bone marrow cells, 3) HT1080, and 4) human gingival fibroblasts were added to ELISA plates coated 
with indicated proteins (35 μM) and incubated at RT for one hour. Samples of bound (extract) and unbound (supernatant) pro-
teins were extracted in SDS sample buffer and analyzed by zymography. Zymography shows that when MMP-2 is added to BSP-
coated plates, both latent and active enzymes are recovered completely in supernatants. BSA and gelatin were used as negative 
and positive MMP-2-binding controls respectively.BMC Cancer 2009, 9:121 http://www.biomedcentral.com/1471-2407/9/121
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MMP-2 binds to the surface of cancer cells via the
fibronectin type II module repeats of the enzyme [29,30].
Despite the lack of an interaction between BSP and
proMMP-2, it is possible that an interaction between BSP
and the αvβ3 integrin itself may trigger downstream sign-
aling events that affect the expression, processing, and
activity of MMP-2. Thus, the requirement of an active
RGD sequence in BSP-mediated cancer cell invasion sug-
gests that BSP binding to the αvβ3 integrin may promote
clustering of integrin molecules, which could activate
downstream signaling events. Notably, ECM proteins can
promote raft formation and type I collagen activates
MMP-2 through β1-integrins, which increases MT1-MMP
levels [21], and by direct binding of pericellular native
type I collagen with the MT1-MMP hemopexin domain
[26]. MT1-MMP enhances focal proteolysis [31] and
experimental metastasis [32], is associated with MMP-2
activation in lung carcinoma [33] and invasive human
breast cancer cell lines [34,35], and is over-expressed in
high-grade gliomas, fibrosarcomas [36] and in carcino-
mas of the lung, stomach, head and neck [37]. However,
in our studies there was no evidence of integrin-mediated
enhancement in the level of MT1-MMP transcript level,
nor in MT1-MMP activity. Evidently, a more complete
understanding of integrin-mediated signaling events will
be important for defining the significance of BSP binding
to the αvβ3 integrin in vivo.
Conclusion
Collectively, using the methods reported here, our studies
do not support a role for BSP in promoting pro-MMP-2
activation.
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